Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

22.78USD
17 Aug 2018
Change (% chg)

-- (--)
Prev Close
$22.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
495,263
52-wk High
$24.18
52-wk Low
$9.03

Latest Key Developments (Source: Significant Developments)

Spectrum Pharma is weighing a sale - Bloomberg
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Spectrum Pharmaceuticals Inc ::SPECTRUM PHARMA IS WEIGHING A SALE - BLOOMBERG CITING SOURCES.  Full Article

Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific
Tuesday, 1 May 2018 

May 1 (Reuters) - Spectrum Pharmaceuticals Inc ::SPECTRUM PHARMACEUTICALS ENTERS INTO A NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC.SPECTRUM PHARMACEUTICALS INC - ENTERED INTO AN AGREEMENT WITH THERMO FISHER SCIENTIFIC.SPECTRUM PHARMACEUTICALS - AGREEMENT TO LEVERAGE ONCOMINE DX TARGET TEST AS COMPANION DIAGNOSTIC FOR SPECTRUM'S NOVEL PAN-HER INHIBITOR POZIOTINIB.  Full Article

Spectrum Pharma Q4 Loss Per Share $0.29
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Spectrum Pharmaceuticals Inc ::SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS AND PIPELINE UPDATE.Q4 NON-GAAP LOSS PER SHARE $0.23.Q4 LOSS PER SHARE $0.29.SEES FY 2018 REVENUE $90 MILLION TO $110 MILLION.Q4 REVENUE $28.6 MILLION.  Full Article

Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update.Q3 non-GAAP loss per share $0.11.Q3 loss per share $0.22.Q3 revenue $36.4 million.  Full Article

Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2.  Full Article

BRIEF-Spectrum Pharmaceuticals Reports Q1 Non-GAAP Loss Per Share $0.15

* SPECTRUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE UPDATE